
Loss of exclusivity is predictable, yet many portfolios treat it as a surprise. Understanding how generic entry plays out in a given market is the[…]

A price negotiation is won or lost on preparation. By the time you are in the room, the important decisions about what you can offer,[…]

An economic model is an argument expressed in numbers. Payers rarely reject the arithmetic; they reject the assumptions, and the assumptions they cannot see are[…]

The quality-adjusted life year looks simple: time lived, weighted by the quality of that time. In practice, the utility values behind it are among the[…]

The comparator is the most consequential choice in a value dossier. A strong result against the wrong comparator is, to a payer, no result at[…]

A payer value dossier is not a regulatory dossier with a different cover. It answers a different question: not whether the medicine is safe and[…]

Assessors increasingly ask whether a trial measured what matters to patients. Patient-reported outcomes can strengthen a reimbursement case, but only if they were planned, validated[…]

Companies often ask what cost per QALY will be accepted in Europe. The honest answer is that there is no single figure, and the better[…]

A single treatment with lasting benefit creates a problem that conventional budgets are not built to solve: a large cost paid today for benefit that[…]

Reimbursing software is not the same as reimbursing a medicine or a device. Germany’s DiGA pathway remains the clearest European example of a dedicated route,[…]